For the millions of adults living with both significant coronary artery disease and severe aortic stenosis, deciding when to treat blocked coronary arteries during a transcatheter valve procedure has long been a clinical judgment call with surprisingly little high-quality evidence behind it. This randomized trial from the New England Journal of Medicine may substantially reframe that decision-making framework.
The TAVI-PCI trial enrolled patients with severe aortic stenosis who also had significant coronary artery disease requiring percutaneous coronary intervention. Participants were randomized to either concomitant PCI — performed at the same procedural setting as TAVI — or staged PCI, conducted as a separate procedure either before or after valve implantation. The trial tracked hard cardiovascular endpoints including death, myocardial infarction, stroke, and unplanned revascularization over a defined follow-up window. The primary composite outcome data revealed meaningful differences in procedural burden and event rates between the two timing strategies, with the staged approach yielding notably distinct outcomes on specific endpoints.
The question of PCI timing during TAVI is more consequential than it might initially appear. Coronary artery disease coexists in roughly 40–75% of TAVI candidates, who tend to be older and frailer than typical cardiac surgery patients, making every additional procedural exposure meaningful. Current guidelines offer only weak, consensus-based recommendations on this topic, largely due to prior evidence gaps. This trial is among the most rigorous head-to-head comparisons yet conducted and carries genuine potential to shift clinical practice guidelines. Key limitations worth noting include the complexity of defining which coronary lesions truly warranted intervention — a judgment that itself introduces variability — and whether findings generalize across different TAVI platforms and global practice settings. Overall, this represents a paradigm-relevant contribution to structural heart disease management rather than an incremental refinement.